Abstract
The transcription factor forkhead box M1 (FOXM1) is a validated oncoprotein in solid cancers, but its role in malignant plasma cell tumors such as multiple myeloma (MM) is unknown. We analyzed publicly available MM data sets and found that overexpression of FOXM1 prognosticates inferior outcome in a subset (~15%) of newly diagnosed cases, particularly patients with high-risk disease based on global gene expression changes. Follow-up studies using human myeloma cell lines (HMCLs) as the principal experimental model system demonstrated that enforced expression of FOXM1 increased growth, survival and clonogenicity of myeloma cells, whereas knockdown of FOXM1 abolished these features. In agreement with that, constitutive upregulation of FOXM1 promoted HMCL xenografts in laboratory mice, whereas inducible knockdown of FOXM1 led to growth inhibition. Expression of cyclin-dependent kinase 6 (CDK6) and NIMA-related kinase 2 (NEK2) was coregulated with FOXM1 in both HMCLs and myeloma patient samples, suggesting interaction of these three genes in a genetic network that may lend itself to targeting with small-drug inhibitors for new approaches to myeloma therapy and prevention. These results establish FOXM1 as high-risk myeloma gene and provide support for the design and testing of FOXM1-targeted therapies specifically for the FOXM1High subset of myeloma.
Similar content being viewed by others
Introduction
The prognosis of patients with multiple myeloma (MM), a difficult-to-cure blood cancer, depends in large measure on the genetic makeup of the myeloma cell. This is reflected in risk stratification models that consider cytogenetic features of myeloma, such as occurrence of oncogene-activating chromosomal translocations, and molecular features, such as gene expression changes1 measured with the assistance of the UAMS-70,2 EMC-92(ref. 3) or REL-17(ref. 4) gene test, to assign newly diagnosed cases to either standard- or high-risk groups. The distinction is clinically relevant because patients with high-risk myeloma have poor outcomes. Whereas overall survival (OS) for patients with standard-risk myeloma is 6–7 years, that for high-risk disease is no more than 2–3 years—despite the application of aggressive, risk-adapted therapies that include new myeloma drugs and, for eligible patients, high-dose therapy followed by autologous stem cell transplantation.5 The unmet medical need of high-risk myeloma calls for dedicated efforts to elucidate the underlying genetic networks and develop approaches for their therapeutic targeting. This study demonstrates the involvement of the transcription factor forkhead box M1 (FOXM1) in a significant subset of high-risk myeloma (~15%) and suggests that FOXM1 provides a molecularly targeted treatment opportunity specifically for this group of patients.
In 2010, based on its enormous potential for the diagnosis and therapy of solid cancers, the AAAS journal Science bestowed upon FOXM1 the ‘Breakthrough of the Year’ award. FOXM1, a member of the large forkhead box (FOX) family of proteins (n≈50), is a validated oncogene in carcinomas,6 but has received little attention in myeloma and related plasma cell malignancies. Findings implicating FOXM1 in the maintenance and self-renewal of carcinoma stem cells7 have raised the question of whether it is similarly important for the putative myeloma stem cell8—yet the elusiveness of this cell9 stands in the way of resolving the issue. Consistent with results that the expression of FOXM1 is tightly regulated in normal cells to ensure mitotic fidelity throughout the cell cycle,10 deregulated expression of FOXM1 in carcinoma cells leads to centrosome amplification, mitotic catastrophe and other cytogenetic aberrations typically seen in cancer cells.11 Whether FOXM1 governs genomic instability of MM,12 a notorious but ill-explained feature of the neoplasia, is unclear. In diffuse large B-cell lymphoma, in which levels of the FOXM1 mRNA and the encoded protein are high, targeted inhibition of FOXM1 augments cell killing when combined with normally subtoxic doses of the proteasome inhibitor, bortezomib.13 Whether this holds true for MM has not been established.
Our interest in FOXM1 began with a comparative gene expression analysis of B-lymphoma counterparts in humans and mice, implicating the transcription factor in an evolutionarily conserved pathway of neoplastic B-cell development.14 Further encouraged by new evidence indicating that FOXM1 (1) drives tumor development and progression15, 16, 17, 18, 19 by virtue of a complex mechanism that includes enhanced cell proliferation, migration and invasion,6 regulation of the DNA damage response20 and changes in the cancer epigenome,21 (2) promotes cancer cell resistance to ionizing radiation22 and cytotoxic drugs,23 (3) governs, in part, the survival and tissue-regenerating capacity of both normal hematopoietic stem cells24 and malignant stem cell-like cells,25 (4) links acquired resistance to cancer therapy with cancer stemness26 and (5) owing to the development of specific small-molecule inhibitors,27 it may soon be targeted more effectively than possible in the past;28 we here decided to evaluate whether FOXM1 might have an important but heretofore overlooked role in plasma cell myeloma.
Materials and methods
FOXM1 expression and survival analysis in patients with myeloma
Levels of FOXM1 mRNA in myeloma cells were determined using Affymetrix U133Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA) as described previously.1 Results are available in the NIH Gene Expression Omnibus (GEO) under accession number GSE2658. Microarray data on monoclonal gammopathy of undetermined significance and normal plasma cells are available at GSE5900. Statistical analysis of microarray results relied on GCOS1.1 software (Affymetrix), including log-rank tests for univariate association with disease-related survival.
HMCLs, antibodies and reagents
Human myeloma cell line (HMCLs), designated H929 or APR1, were chosen for studies on inducible knockdown (KD) of FOXM1. HMCLs, CAG or XG1 were used for studies on constitutive overexpression (OE) of FOXM1. All four cell lines had secretion of IgA29, 30, 31, 32 and in vitro culture conditions (37 °C, 5% CO2) in common. Oncogene-activating chromosomal translocations took the form of t(4;14) in case of H929 cells,33 t(11;14) in XG1 cells30 and t(14;16) in ARP1 and CAG cells.33, 34 Gene expression spikes on microarrays corresponded to the translocation status: FGFR3 and WHSC1 (better known as MMSET) in case of H929 cells, CCND1 (cyclin D1) in XG1 cells and MAF (c-MAF) in ARP1 and CAG cells.35 The status of the tumor suppressor p53 was wild type in case of H929 cells,36 mutated in XG1 cells37 and null in ARP1 and CAG cells.34 Antibodies for western blotting were purchased from Santa Cruz Biotechnology (Dallas, TX, USA) (FOXM1, catalog number sc-500; CDK6 (cyclin-dependent kinase 6), sc-7961; β-actin, sc-47778) or Cell Signaling Technology (Danvers, MA, USA) (caspase-8, 4927; cleaved caspase-8, 9496; caspase-9, 9502; caspase-3, 9668; cleaved caspase-3, 9661; PARP, 9542). Dox and thiostrepton (TS) were from Sigma-Aldrich (St Louis, MO, USA).
Quantitative, reverse transcription polymerase chain reaction
Total RNA was extracted using Quick-RNA MiniPrep (Zymo Research, Irvine, CA, USA) and reverse transcribed using oligo dT primers and SuperScript III RT (Invitrogen, Carlsbad, CA, USA). Data analysis relied on the ΔΔCt method. Primers were purchased from Integrated DNA Technologies (Coralville, IA, USA). Sequences are available upon request.
Western blotting and co-immunoprecipitation assays
Whole myeloma cell lysates were prepared using the Mammalian Cell Extraction Kit (K269-500) from Biovision (Milpitas, CA, USA). Proteins (30 μg per sample) were fractionated on 4–12% polyacrylamide gels blocked with 5% non-fat milk in Tris-buffered saline containing 0.05% Tween-20. Proteins were transferred to nitrocellulose membranes, incubated with primary antibody (dilution 10−3) overnight (4 °C) and visualized with horse radish peroxidase-conjugated secondary antibody using SuperSignal West Pico (Pierce Biotechnology, Rockford, IL, USA). Blots were stripped, reprobed for β-actin and evaluated by densitometry to estimate protein abundance. Co-immunoprecipitations (co-IPs) using the Pierce Direct Magnetic IP/Co-IP Kit (Thermo Scientific, Rockford, IL, USA) and antibodies to FOXM1 and CDK6 were performed as recently described.38 IgG from Bethyl Laboratories (Montgomery, TX, USA) was used as control.
Soft-agar clonogenicity assay
Clonogenic growth of myeloma was evaluated by seeding 1 × 104 cells in 0.5 ml RPMI 1640 (Invitrogen) supplemented with 0.33% agar and 10% FBS. Cells were grown in vitro (37 °C, 5% CO2) for 3 weeks, replenishing cell culture medium twice weekly. In some cases, cells were treated during weeks 2 and 3 with the FOXM1-inhibiting thiazole antibiotic, TS. Cell clones, defined as tight aggregates of ⩾40 myeloma cells, were enumerated using photographic images of soft-agar plates uploaded to Image J.
Cell proliferation and viability
Cell proliferation rate and viability were determined in 6-well plates using a hemacytometer and the trypan blue exclusion assay (0.4% dye in phosphate-buffered saline, pH 7.3).
Myeloma xenografts in immune-compromised laboratory mice
To evaluate the impact of FOXM1 KD on myeloma growth, 2 × 106 H929 cells expressing either normal (FOXM1N) or reduced (FOXM1KD) levels of FOXM1 were injected subcutaneously into the right and left flank, respectively, of NSG (NOD scid gamma) mice (Jackson Laboratory, Bar Harbor, ME, USA). To induce FOXM1 KD in incipient tumors, Dox (2 mg/ml) was added to the drinking water, beginning on day 10 following myeloma cell transfer.
Similarly, to assess the effect of FOXM1 OE on myeloma growth, paired samples of CAG cells (2 million in each flank) that expressed either elevated levels of FOXM1 (FOXM1OE) or normal levels (FOXM1N) were transferred subcutaneously to NSG mice (Jackson Laboratory). After 10 days, some mice were treated with intraperitoneal administrations of TS (30 mg/kg) twice weekly. In all cases, tumor growth was measured two to three times weekly, using a pair of calipers. Mice were killed using CO2 asphyxiation when tumors reached 20 mm in diameter. All studies were approved under protocol 1301010 of the Institutional Animal Care and Use Committee of The University of Iowa.
Statistical analysis
Two-tailed Student’s t-test was used to compare two experimental groups. One-way analysis of variance was used to evaluate more than two groups. The Kaplan–Meier method was used to determine myeloma patient survival in accordance with FOXM1 expression. In all cases, P⩽0.05 was considered significant.
Results
Heightened FOXM1 expression predicts poor survival in patients with myeloma
To evaluate the possibility that FOXM1 is important for myeloma, we analyzed a well-annotated, mature data set, designated total therapy 2 (TT2), for which microarray-based gene expression and clinical outcome data were available. The levels of FOXM1 in 351 patients with newly diagnosed myeloma from that data set are presented in Figure 1a, according to increasing gene expression. With 200 units of FOXM1 message used as a cutoff, the great majority of cases (316/351, 90%) exhibited the same expression levels seen in normal plasma cells from the bone marrow (BM; n=22) or in BM plasma cells from individuals with monoclonal gammopathy of undetermined significance (n=44), a precursor of frank myeloma.39 However, in 10% of myelomas (35/351) FOXM1 levels were grossly elevated. The distinction between high and low FOXM1 was of prognostic significance, as both event-free survival (EFS) and OS were reduced in cases exhibiting high FOXM1 expression (Figure 1b). A very similar fraction of ‘FOXM1High’ myelomas (18/149, 12.1%; Supplementary Figure 1a) associated with the same kind of survival disadvantage (Supplementary Figure 1b) was seen in the Total Therapy 3 (TT3) cohort, which comprised intensively treated patients (n=149) who had received tandem autologous stem cell transplantation and bortezomib/thalidomide-based induction and maintenance.40 Similarly, elevated FOXM1 message predicted poor OS of patients with myeloma (n=247) treated upfront using high-dose therapy/autologous stem cell transplantation at the University of Heidelberg (Heidelberg, Germany) (Supplementary Figure 2).41 In agreement with the variable FOXM1 message levels seen in TT2/3 myelomas, a pilot immunolabeling study of archival myeloma-laden BM sections pointed to variable amounts and distribution patterns of FOXM1 protein in myeloma cells (Supplementary Figure 3). These findings indicated that upregulation of FOXM1 in a subset of myeloma (10–12%) leads to inferior outcome.
FOXM1 is a high-risk myeloma gene
We asked whether heightened FOXM1 expression in the TT2 cohort might be associated with a particular molecular subgroup of myeloma. Figure 1c presents the mean values of FOXM1 levels in eight widely recognized subgroups, showing that elevated FOXM1 was particularly prevalent in two known to confer high risk in terms of clinical course and outcome: MAF/MAFB (MF) and proliferation (PR). A more recently developed molecular genetic approach to distinguishing high- and standard-risk disease, that is, the UAMS-70 gene signature,2 afforded another way of testing whether upregulated FOXM1 might be a feature of high-risk myeloma. Statistical comparison of the mean FOXM1 levels in the 46 and 305 cases identified as high and standard risk according to this signature supported this contention (Figure 1d). In sync with that, not only was FOXM1High status statistically linked (χ2 contingency analysis) with a positive score in the 70-gene test (P<10−4) but almost two-thirds of the UAMS-70 high-risk cases (29/46, 63%) fell into the PR (n=20) and MF (n=9) subgroups of myeloma (indicated by red squares in Figure 1c, bottom). The TT3 myelomas exhibited the same preponderance of FOXM1High in the MF/PR subgroups and the same association of FOXM1High status and positive 70-gene test score seen in the TT2 sample (Supplementary Figures 1c and d). The findings in more than 500 myelomas from the TT2/3 studies led us to conclude that FOXM1 is a bona fide high-risk myeloma gene.
Inducible downregulation of FOXM1 inhibits myeloma cells in vitro
Following up on the clinical observations described above, we decided to elucidate the role of FOXM1 in myeloma biology using two independent HMCLs, designated H929 and ARP1, that harbored ample amounts of FOXM1 protein. To evaluate whether short hairpin RNA (shRNA)-mediated KD of FOXM1 message blunts the growth and survival of myeloma, we transduced H929 and ARP1 cells with lentivirus that encoded a FOXM1-targeted shRNA under the control of a Dox-inducible gene promoter: FOXM1KD cells. Cells transduced with a Dox-inducible ‘scrambled’ shRNA, not targeting any expressed gene in mice and therefore leaving FOXM1 at normal levels (N), were used as control: FOXM1N cells. Quantitative, reverse transcription-PCR ((qRT-PCR) and western blot analyses demonstrated successful KD of FOXM1 in both cell lines at the mRNA (Figure 2a) and protein (Figure 2b) level. Significant reductions in FOXM1KD cell numbers, relative to FOXM1N controls, after 2, 3 and 4 days of Dox-dependent expression of shRNA indicated that partial loss of FOXM1 hampers myeloma growth in vitro (Supplementary Figure 4a). The diminished growth rate of FOXM1KD cells was attributed to both increased apoptotic cell death evidenced by increased proteolytic cleavage of poly (ADP-ribose) polymerase and caspases 3, 8 and 9 (Supplementary Figure 4b) and reduced cell cycle progression. The latter was revealed by flow cytometric analysis of DNA content that demonstrated an increase of cells in the G1 phase and a concomitant decrease in the S and G2/M phases (not shown). Soft-agar clonogenicity assays demonstrated a striking (~7-fold) drop in size and number of FOXM1KD versus FOXM1N colonies: 0.88% vs 6.4% in case of H929 cells and 0.92% vs 6.0% in case of ARP1 cells (Figure 2c). These results suggested that FOXM1 regulates, in part, the growth and survival of myeloma cells.
Genetic targeting of FOXM1 retards myeloma growth in mice
To determine whether inducible KD of FOXM1 inhibits myeloma in vivo, we xenografted FOXM1KD and FOXM1N H929 cells under the skin of the left and right abdominal flank of NSG mice (n=5), respectively. Ten days after in vivo transfer of two million cells to each side, the mice were administered Dox in the drinking water to induce the expression of FOXM1-targeted or scrambled shRNA in the malignant plasma cells (Figure 3a, top). Tumor diameters were measured daily, using a pair of calipers, to compare the growth rate of the paired FOXM1KD and FOXM1N xenografts. In five of five hosts, the FOXM1KD tumors harvested on day 28 (end point of study) were visibly smaller than their FOXM1N counterparts (Figure 3a, bottom). The mean weight of FOXM1KD tumors (1.24 g) was 35% lower compared with that of FOXM1N tumors (1.91 g; Figure 3b). Compared with FOXM1N tumors, FOXM1KD tumors contained reduced amounts of FOXM1 protein (Figure 3c). Comparison of growth rates demonstrated that the FOXM1KD tumors lagged behind their FOXM1N counterparts (Figure 3d), indicating stable expression of the FOXM1-targeted shRNA during the 28-day growth period. These results demonstrated that genetic targeting of FOXM1 inhibits myeloma in vivo.
Enforced expression of FOXM1 promotes myeloma in vitro
To complement the KD studies described above with the opposite experimental approach, we assessed whether enforced transgenic expression of FOXM1 might enhance myeloma growth. To that end, we transfected two independent HMCLs containing moderate amounts of FOXM1 protein, CAG and XG1, with lentivirus that encoded a FOXM1 cDNA gene under control of the EF1α promoter. Compared with cells transduced with noncoding ‘empty’ virus that left FOXM1 levels unchanged (FOXM1N, used as control), cells overexpressing FOXM1 (FOXM1OE) contained elevated amounts of FOXM1 message (Figure 4a, top) and FOXM1 protein (Figure 4a, bottom). Upregulation of FOXM1 promoted cell growth (Figure 4b), which was abolished by the FOXM1-inhibiting thiazole antibiotic, TS42 (Supplementary Figure 5a). Increased growth of FOXM1OE cells was attributed to enhanced cell cycle progression (not shown) and survival. The latter was reflected by less pronounced activation of PARP and caspases in FOXM1OE cells compared to FOXM1N cells (Figure 4c). Clonogenic growth in soft agar was moderately heightened (by ~30%) in untreated FOXM1OE vs FOXM1N cells, but more significantly elevated (2–3-fold) in TS-treated FOXM1OE vs FOXM1N cells (Supplementary Figures 5b and c). These results agreed with the FOXM1 KD studies and strengthened the contention that FOXM1 regulates growth and survival of myeloma cells in vitro.
OE of FOXM1 promotes myeloma xenografts in NSG mice
We transferred FOXM1OE and FOXM1N CAG cells to NSG mice treated with TS or left untreated (Figure 5a, top). In all cases, FOXM1OE tumors harvested at study endpoint (day 28) were larger than the FOXM1N tumors (Figure 5a, bottom). In untreated mice, the mean weight of FOXM1OE tumors (3.97 g) was significantly higher compared with that of FOXM1N tumors (0.848 g): a ratio of 4.7 (Figure 5b). The OE-to-N ratio (2.03 g/0.432 g, 4.7) was the same in TS-treated mice (Figure 5b), which agreed with the expectation that TS inhibits FOXM1-expressing tumors, but did not support the possibility that FOXM1OE tumors were more sensitive to the drug compared with that of their FOXM1N counterparts. In both TS-treated and -untreated mice, FOXM1OE tumors contained elevated levels of FOXM1 protein relative to FOXM1N controls (Figure 5c). Time-course analyses of tumor size, analogous to those carried out in the KD studies, underlined the myeloma-promoting effect of FOXM1. Using the area under the curve as metric, growth rates of FOXM1OE tumors (198) were elevated by 77% in TS-treated mice compared with FOXM1N tumors (112; Figure 5d). Similarly, in untreated mice, growth rates of FOXM1OE tumors (250) were 83% higher compared with that of FOXM1N tumors (137; Figure 5d). These results added confidence to the contention that FOXM1 promotes myeloma in vivo, yet also indicated that TS may not be as active in mice as it is in vitro.
Coordinated expression of FOXM1 and CDK6 in myeloma
To elucidate the mechanism by which FOXM1 promotes myeloma, we followed up on publicly available UCSC ChIP-Seq results and published findings,43 both indicating that CDK6 is a transcriptional target of FOXM1 in normal and malignant cells. There is also strong evidence that FOXM1 is a direct phosphorylation target of CDK6 in cancer, suggesting a positive autoregulatory FOXM1-CDK6 feedforward loop that supports the malignant state.44 Co-IP analysis of FOXM1OE CAG and XG1 cells—which demonstrated that antibody to CDK6 (bait) pulled down FOXM1 (Figure 6a, top), whereas antibody to FOXM1 (bait) pulled down CDK6 (Figure 6a, bottom)—pointed to physical interaction of both proteins in myeloma cells. Codetection of FOXM1 and CDK6 in FOXM1OE CAG cells by means of immunofluorescence microscopy supported this interpretation (not shown). qRT-PCR (Figure 6b, top) and western blotting (Figure 6b, bottom) of FOXM1KD and FOXM1N H929 and ARP1 cells showed that FOXM1 and CDK6 expression may be coregulated in myeloma. Consistent with that, pharmacological inhibition of FOXM1 using TS caused a coordinated drop of FOXM1 and CDK6 message in CAG and XG1 cells—more steeply in FOXM1OE than FOXM1N cells (Figure 6c, top). Corresponding changes in FOXM1 protein levels were also seen, but their magnitude was not as high as in case of mRNA (Figure 6c, bottom). In sync with the laboratory findings, FOXM1 and CDK6 expression were correlated in the TT2 and TT3 patient cohorts (Supplementary Figure 5b) and predictive of survival (Supplementary Figure 5c). Interestingly, before adopting the UAMS-70 gene signature for stratifying standard- and high-risk myeloma,2 a 3-gene minisignature had been developed for the same purpose. It relied on CDK6; one of its regulators, CKS1B, which encodes a member of the highly conserved cyclin kinase subunit 1 family of proteins;45 and OPN3 (opsin 3), the role of which in myeloma is obscure (FZ, unpublished result).
Coexpression of FOXM1 and NEK2 in myeloma
To identify additional network genes that may collaborate with FOXM1 in promoting myeloma, we interrogated the MMRC data set available online for genes tightly coexpressed with FOXM1 (Figure 7a). Among the top 10 genes (r2=0.838) was NIMA-related kinase 2 or NEK2. Because NEK2 is not only a well-established transcriptional target of FOXM1 in various cell lineages46, 47 but also a driver of drug resistance in myeloma and other cancers,48, 49, 50 we sought to confirm the coexpression of NEK2 and FOXM1 in independent data sets. This was the case in TT2 and TT3 (Supplementary Figure 6a, left) and also in MMRF’s CoMMpassSM study (Supplementary Figure 6a, right), in which FOXM1High status conferred the same kind of survival disadvantage (Supplementary Figure 6b) seen in the TT2 (Figure 1b) and TT3 (Supplementary Figure 1) cohorts. In the CoMMpassSM data set, NEK2 was among the top 20 differentially expressed genes (P=0.000331) in a 130-gene list (P<0.05) that distinguished FOXM1High from FOXM1Low tumors (Supplementary Figure 6c). Gene set enrichment analysis using this gene list as the input revealed a FOXM1-dependent network of transcription factors, DNA replication and cell division pathways in myeloma (Supplementary Figure 6d). These in silico findings prompted us to determine whether FOXM1 and NEK2 might be coexpressed in the four HMCLs used throughout this study. Western blotting showed that FOXM1 and NEK2 proteins shifted coordinately in accordance with FOXM1 status in four of four cell lines (Figure 7b, top). At the message level, results were less consistent; that is, although NEK2 mRNA dropped upon KD of FOXM1 in H929 and ARP1 cells (Figure 7b, bottom), NEK2 did not rise upon OE of FOXM1 in CAG and XG1 cells (results not shown). Despite the latter finding, FOXM1 and NEK2 expression status was statistically linked with survival in the TT2 cohort (Figure 7c). These results provided evidence that FOXM1 and NEK2 are coregulated in myeloma.
Discussion
The main finding of this study is clinical and experimental evidence for the involvement of FOXM1 in a relatively small (~15%) but aggressive subset of myeloma (chiefly subgroups MF and PR). FOXM1 expands the list of candidate genes uncovered by us35, 38, 48, 51 and others,52, 53 which seem to render myeloma a high-risk disease by regulating pathways of tumor progression and stemness, acquisition of drug resistance and, ultimately, refractory relapse. A distinctive feature of FOXM1, compared with all other candidate genes identified thus far, is its discovery in a comprehensive gene expression analysis of mature B-cell lymphoma counterparts in humans and mice.14 Cross-species analyses of this sort, which afford a unique and powerful approach to identifying genetic networks of neoplastic growth conserved over millions of years of evolution, have been successfully used in research on solid cancers but largely neglected in myeloma.14 The results on FOXM1 reported here demonstrate the utility of this approach for myeloma and suggest that comparative oncogenomics of myeloma-like tumors in genetically engineered mouse models may not only further our understanding of the natural history of myeloma but also reveal new targets for treatment and prevention. The ongoing development of new genetically engineered mouse models54, 55, 56 and continuous refinement of established ones57, 58, 59 are generating great promise along this line.
The results reported here may be summarized in a working model of FOXM1’s function in myeloma (Figure 8a), which considers (1) the gene’s coregulation with CDK6 and NEK2, (2) the output of a network analysis that relied on the GeneMANIA online tool to predict genetic interactions of FOXM1 in myeloma cells (Figure 8b) and (3) the ability of a novel 3-gene minisignature, comprised of FOXM1, CDK6 and NEK2, to prognosticate survival of patients with myeloma (Figure 8c). Although the underlying molecular genetics of the interaction depicted in Figure 8a needs to be elucidated in greater depth, the scheme may provide a useful blueprint for designing combination treatments for FOXM1High myelomas. This may take advantage of small-molecule inhibitors of (a) FOXM1, such as FDI-6, which binds directly to the transcription factor and displaces it from genomic targets in cancer cells,27 (b) CDK6, such as palbociclib, which is not highly specific (it also targets CDK4) but has already demonstrated therapeutic activity (in conjunction with bortezomib and dexamethasone) in a phase 1/2 clinical trial of relapsed/refractory MM60 and (c) NEK2, such as aminopyridine scaffold compounds, which inhibit NEK2’s kinase activity,61 or unrelated inhibitors, which trigger NEK2 degradation indirectly, using a mechanism that involves the disruption of NEK2 binding to kinetochore complex component, NDC80, better known as highly expressed in cancer 1 or HEC1.62 Despite broad cancer-suppressing activities,63 the cyclic oligopeptide antibiotic, TS, which has been used here as a FOXM1-inhibiting compound, is an unlikely candidate for further therapeutic development because its extensive use in veterinary medicine revealed severe toxicity issues.
In conclusion, FOXM1 appears to be a bone fide high-risk myeloma gene that interacts with CDK6 and NEK2 to facilitate myeloma xenografts in mice and promote the growth, clonogenic self-renewal and survival of myeloma cells in vitro. Clinical studies are warranted to further validate FOXM1 as a potential therapeutic target in FOXM1High high-risk myeloma.
References
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028.
Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.
Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012; 26: 2406–2413.
Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R et al. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leuk Lymphoma 2015; 56: 594–601.
Rajkumar SV . Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78–88.
Koo CY, Muir KW, Lam EW . FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28–37.
Gong A, Huang S . FoxM1 and Wnt/beta-catenin signaling in glioma stem cells. Cancer Res 2012; 72: 5658–5662.
Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190–197.
Hajek R, Okubote SA, Svachova H . Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 2013; 163: 551–564.
Wonsey DR, Follettie MT . Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65: 5181–5189.
Laoukili J, Stahl M, Medema RH . FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007; 1775: 92–102.
Neri P, Bahlis NJ . Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opin Biol Ther 2013; 13 (Suppl 1): S69–S82.
Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P et al. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 2012; 97: 1092–1100.
Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A et al. Identification of candidate B-lymphoma genes by cross-species gene expression profiling. PLoS One 2013; 8: e76889.
Kong X, Li L, Li Z, Le X, Huang C, Jia Z et al. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res 2013; 73: 3987–3996.
Cai Y, Balli D, Ustiyan V, Fulford L, Hiller A, Misetic V et al. Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. J Biol Chem 2013; 288: 22527–22541.
Wang Z, Zheng Y, Park HJ, Li J, Carr JR, Chen YJ et al. Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer Ther 2013; 12: 759–767.
Motiwala T, Kutay H, Zanesi N, Frissora FW, Mo X, Muthusamy N et al. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia 2015; 29: 1350–1359.
Kopanja D, Pandey A, Kiefer M, Wang Z, Chandan N, Carr JR et al. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features. J Hepatol 2015; 63: 429–436.
Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW . FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta 2014; 1839: 1316–1322.
Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW et al. FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One 2012; 7: e34329.
Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM et al. Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells. Radiat Res 2014; 182: 420–429.
Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene 2016; 35: 1433–1444.
Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang Z et al. The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells. Nat Immunol 2015; 16: 810–818.
Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD et al. FoxM1 drives a feed-forward STAT3-activation signaling loop that promotes the self-renewal and tumorigenicity of glioblastoma stem-like cells. Cancer Res 2015; 75: 2337–2348.
Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC et al. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 2015; 6: 2349–2365.
Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinkovic D et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun 2014; 5: 5165.
Halasi M, Gartel AL . Targeting FOXM1 in cancer. Biochem Pharmacol 2013; 85: 644–652.
Gazdar AF, Oie HK, Kirsch IR, Hollis GF . Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 1986; 67: 1542–1549.
Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654–3663.
Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS . Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044–3052.
Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006; 66: 7661–7667.
Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226–238.
Yellapantula V, Divya T, Dinu V, Scotch M . Informatics approaches for integrative analysis of disparate high-throughput genomic datasets in cander. Arizona State University (ASU) Electronic Dissertations and Theses Digital Repository, 2014.
Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H et al. RARalpha2 expression confers myeloma stem cell features. Blood 2013; 122: 1437–1447.
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199.
Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007; 21: 1070–1078.
Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E et al. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res 2015; 75: 594–604.
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM . A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418–5422.
van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220–1227.
Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 2012; 120: 1087–1094.
Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S . The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 2011; 3: 725–731.
Sanders DA, Gormally MV, Marsico G, Beraldi D, Tannahill D, Balasubramanian S . FOXM1 binds directly to non-consensus sequences in the human genome. Genome Biol 2015; 16: 130.
Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620–634.
Chang H, Jiang N, Jiang H, Saha MN, Qi C, Xu W et al. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica 2010; 95: 1542–1547.
Nischalke HD, Schmitz V, Luda C, Aldenhoff K, Berger C, Feldmann G et al. Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures. PLoS One 2012; 7: e42141.
Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009; 58: 679–687.
Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013; 23: 48–62.
Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F . Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep 2014; 31: 745–754.
Marina M, Saavedra HI . Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed) 2014; 19: 352–365.
Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010; 1: 22–33.
Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G et al. Growth Differentiating Factor 15 enhances the tumor initiating and self-renewal potential of multiple myeloma cells. Blood 2013; 123: 725–733.
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun 2015; 6: 7539.
Hu Y, Zheng M, Gali R, Tian Z, Topal Gorgun G, Munshi NC et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J 2013; 3: e156.
Dechow T, Steidle S, Gotze KS, Rudelius M, Behnke K, Pechloff K et al. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 2014; 124: 5263–5274.
Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM et al. Adoptive B-cell transfer mouse model of human myeloma. Leukemia 2016; 30: 962–966.
Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376–385.
Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17: 7313–7323.
Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F et al. (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J 2013; 3: e165.
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA et al. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma 2015; 56: 3320–3328.
Innocenti P, Woodward H, O'Fee L, Hoelder S . Expanding the scope of fused pyrimidines as kinase inhibitor scaffolds: synthesis and modification of pyrido[3,4-d]pyrimidines. Org Biomol Chem 2015; 13: 893–904.
Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B et al. Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene 2015; 34: 1220–1230.
Bhat UG, Halasi M, Gartel AL . FoxM1 is a general target for proteasome inhibitors. PLoS One 2009; 4: e6593.
Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 2015; 125: 90–101.
Acknowledgements
The expert technical assistance by Dr Xuefang Jing and the provision of NSG mice by Dr Weizhou Zhang (both Department of Pathology, University of Iowa) are gratefully acknowledged. Research funding in Germany (Heidelberg) was provided by the Dietmar Hopp Stiftung (Walldorf), the Systems Medicine program of the German Ministry of Education and Science (CLIOMMICS 01ZX1309), and the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich/Transregio TRR79). This work was supported in part by NIH Training Grant T32-HL07734 and National Natural Science Foundation of China (NNSFC) Grant 81250110552 (both to VT); by NCI R01CA152105, Leukemia & Lymphoma Society Translational Research Program Awards 6246-11 and 6094-12, NNSFC Award 81228016, Multiple Myeloma Research Foundation Senior Research Program Award 2015 and International Myeloma Foundation Senior Research Program Award 2015 (all to FZ); by institutional start-up funds from the Department of Internal Medicine, CCOM, UI (to FZ and GT); by NCI Core Grant P30CA086862 in support of The University of Iowa Holden Comprehensive Cancer Center; and by NCI R01CA151354 (to SJ).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Gu, C., Yang, Y., Sompallae, R. et al. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia 30, 873–882 (2016). https://doi.org/10.1038/leu.2015.334
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.334
- Springer Nature Limited
This article is cited by
-
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
Journal of Experimental & Clinical Cancer Research (2022)
-
FOXM1 regulates glycolysis and energy production in multiple myeloma
Oncogene (2022)
-
Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
npj Precision Oncology (2021)
-
Overexpression of aberrant Wnt5a and its effect on acquisition of malignant phenotypes in adult T-cell leukemia/lymphoma (ATL) cells
Scientific Reports (2021)
-
BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis
Cancer Gene Therapy (2020)